New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 24, 2012
10:25 EDTAGN, VPHM, TWX, RBCN, STR, PVH, LAMR, CTB, BODY, RHIOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Allergan (AGN) upgraded to Outperform from Underperform at CLSA... Body Central (BODY) upgraded to Outperform from Perform at Oppenheimer... Cooper Tire (CTB) upgraded to Buy from Hold at Deutsche Bank... Lamar Advertising (LAMR) upgraded to Outperform from Market Perform at Wells Fargo... PVH Corp. (PVH) upgraded to Overweight from Neutral at Piper Jaffray... Questar (STR) upgraded to Buy from Neutral at UBS... Rubicon (RBCN) upgraded to Neutral from Sell at Goldman... Time Warner (TWX) upgraded to Overweight from Equal Weight at Morgan Stanley... ViroPharma (VPHM) upgraded to Outperform from Market Perform at Wells Fargo... Robert Half (RHI) upgraded to Buy from Neutral at BofA/Merrill.
News For AGN;BODY;CTB;LAMR;PVH;STR;RBCN;TWX;VPHM;RHI From The Last 14 Days
Check below for free stories on AGN;BODY;CTB;LAMR;PVH;STR;RBCN;TWX;VPHM;RHI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 22, 2014
06:45 EDTAGNJudge refuses to prevent special Allergan shareholder meeting, NY Times says
Subscribe for More Information
August 21, 2014
06:00 EDTTWXStocks with implied volatility below IV index mean; TWX WAG
Subscribe for More Information
August 20, 2014
17:59 EDTAGNAllergan talks with Salix in defense tactic said to be dormant, Bloomberg says
Subscribe for More Information
17:35 EDTAGNAllergan said to explore options outside of Salix acquisition, Bloomberg says
Subscribe for More Information
10:53 EDTAGNAnalysts say Salix takeover would boost Allergan
Subscribe for More Information
09:46 EDTAGNAllergan merger deal not imminent, CNBC's Faber reports
An acquisition by Allergan (AGN) is not imminent, CNBC's David Faber reports. Salix (SLXP) and Jazz Pharmaceuticals (JAZZ) are said to be potential targets of the company, Faber adds. Valeant (VRX) could announce over the next few days that it has enough votes to call for a special meeting, the reported said.
07:19 EDTAGNPossible Allergan Salix deal could be 8% accretive in '15-'16, says Wells Fargo
After The Wall Street Journal reported that Allergan (AGN) had approached Salix (SLXP) and other companies about a potential acquisition, Wells Fargo thinks that a largely debt financed purchase of Salix could be 8% accretive for Allergan in 2015-2016, reaching 12% accretion in 2018.
07:07 EDTAGNSome Valeant shareholders express uncertainty over Allergan deal, Reuters says
Subscribe for More Information
07:04 EDTAGNSalix buyout price could be near $192 per share, says William Blair
William Blair believes a combined Allergan (AGN) and Salix (SLXP) would be very attractive. The firm estimates a potential takeover price for Salix towards the high end of its $176-$192 per share range. Salix rose 16% yesterday to $160.80 after Wall Street Journal reported that Allergan approached the company and at least one other about a takeover.
August 19, 2014
17:14 EDTAGNOn The Fly: Closing Wrap
Subscribe for More Information
16:52 EDTAGNAllergan all-cash deal would reduce hostile bid chances, says BMO Capital
Subscribe for More Information
14:40 EDTAGNSterne Agee says Allergan could pay up to $190 for Salix and still be accretive
Subscribe for More Information
13:13 EDTAGNAllergan approached Salix, one other about takeover, WSJ reports
Subscribe for More Information
13:06 EDTAGNSalix jumps 6% to $147.85 after WSJ report of Allergan approach
Subscribe for More Information
13:05 EDTAGNAllergan approached Salix about takeover, WSJ reports
07:50 EDTRHIRobert Half and Kforce weakness a buying opportunity, says Macquarie
Macquarie recommends using recent weakness in Robert Half (RHI) and Kforce (KFRC) related to global macro uncertainty as a buying opportunity.
August 18, 2014
15:59 EDTAGNAllergan CFO change may suggest strategic deal near, says BMO Capital
BMO Capital believes former Allergan (AGN) CFO Jeff Edwards would not be leaving if a change of control of the company, such as a takeover by Valeant (VRX), were in the future. Rather, BMO thinks Edwards' decision to leave could be a sign that a strategic transaction marking a new chapter in Allergan's growth may be nearing. The firm thinks Allergan is in capable hands with new CFO Jim Hindman and it keeps an Outperform rating on the stock with a $230 price target.
11:57 EDTAGNAllergan CFO departure largely unexpected, says Wells Fargo
Subscribe for More Information
09:02 EDTAGNAllergan names Jim Hindman as CFO, effective immediately
Subscribe for More Information
07:57 EDTAGNCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use